SERUM LEVELS OF CANCER-ASSOCIATED ANTIGEN CA-195 IN GASTROINTESTINAL CANCERS AND ITS COMPARISON WITH CA19-9
SERUM LEVELS OF CANCER-ASSOCIATED ANTIGEN CA-195 IN GASTROINTESTINAL CANCERS AND ITS COMPARISON WITH CA19-9
复制标题
DOI：
10.1002/jcla.1860030610
复制
发表时间：
1989-01-01
影响因子：
2.7
通讯作者：
GAUR, P
中科院分区：
文献类型：
--
作者：
BHARGAVA, AK;PETRELLI, NJ;GAUR, P
抗CA-195的抗体结合于由Lewis A和唾液酸化Lewis A血型抗原组成的表位，而CA19-9对唾液酸化Lewis A血型抗原具有特异性。检测52例正常人、65例良性疾病患者、74例非胃肠道肿瘤患者、149例结直肠癌患者和119例上消化道肿瘤患者的血清CA19-9和CA-195水平，以探讨其与疾病状态的关系。在正常受试者中，这两种标记物的发生率都很低；然而，在良性疾病组中，CA19-9的去落率略高。在结直肠癌患者中，CA-195对原发和晚期疾病显示出更高的敏感性。在上消化道癌症患者中，这两种标志物的水平显示出相似的升高发生率。基于这些结果，不能排除CA-195的LEA特异性的贡献，它可以单独或与其他标志物一起用于监测结直肠癌、胰腺癌、胃胆、胆管和肝癌患者。
The antibody against CA-195 binds to an epitope that consists of both Lewis A and sialylated Lewis A blood group antigen, whereas CA19-9 has shown specificity for sialylated Lewis A blood group antigen. CA19-9 and CA-195 levels were measured in the sera of 52 normal subjects; 65 benign disease patients; and 74 non-gastrointestinal, 149 colorectal, and 119 upper gastrointestinal cancer patients to correlate their levels with disease status of the patients. Low incidence were found among normal subjects for both markers; however, in the benign disease group a slightly higher incidence of elelvation was seen for CA19-9. Among colorectal cancer patients CA-195 appeared to show higher sensitivity for primary as well as advanced disease. Levels of both markers showed similar incidences of elevation among upper gastrointestinal cancer patients. Based on these results the contribution of Lea specificity of Ca-195 cannot be ruled out, and it may be used alone or in combination with other markers for monitoring of patients with colorectal, pancreatic, gastric gall bladder, bile duct, and liver cancers.